We aimed to evaluate the efficacy and safety of intrathecal pemetrexed (IP) for treating EGFR-mutant leptomeningeal metastases (LMs) from EGFR-mutant NSCLC. The RD observed in the phase 1 study was 50 mg pemetrexed. A total of 30 cases of LM-NSCLC were enrolled in the phase 2 study, including 14 males and 16 females. Four patients did not survive for 4 weeks and could not be evaluated for efficacy. The clinical response rate was 84.6% (22 of 26). The median overall survival of all patients was 9.0 months (n = 30, 95% confidence interval: 6.6–11.4 mo). Most AEs were mild, and the most frequent AE of any grade was myelosuppression (n = 9, 30%), which returned to normal after symptomatic treatment. This study revealed that 50 mg pemetrexed is the RD which results in few AEs and a good response rate. IP is an effective treatment for patients with EGFR-mutant NSCLC-LM who had failed on tyrosine kinase inhibitor...... READ ARTICLE
Journal of Thoracic Oncology DOI:10.1016/J.JTHO.2021.04.018
Authors: Chengjuan Fan, Qiuyu Zhao, Li Li, Weixi Shen, Yang Du, Chong Teng, Feng Gao, Xiaowei Song, Qiuying Jiang, Dayong Huang, Yinghua Jin, Yanju Lv, Lingxiao Wei, Tengfei Shi, Xue Zhao, Naisheng Gao, Zhengjun Jiang, Tao Xin
